--- provider: falcon model: Edison Scientific Literature cached: false start_time: '2026-06-03T12:14:56.772524' end_time: '2026-06-03T12:23:30.245996' duration_seconds: 513.47 template_file: templates/gene_research_go_focused.md template_variables: organism: human gene_id: ARNT gene_symbol: ARNT uniprot_accession: P27540 protein_description: 'RecName: Full=Aryl hydrocarbon receptor nuclear translocator {ECO:0000305}; Short=ARNT protein; AltName: Full=Class E basic helix-loop-helix protein 2; Short=bHLHe2; AltName: Full=Dioxin receptor, nuclear translocator; AltName: Full=Hypoxia-inducible factor 1-beta; Short=HIF-1-beta; Short=HIF1-beta;' gene_info: Name=ARNT {ECO:0000312|HGNC:HGNC:700}; Synonyms=BHLHE2; organism_full: Homo sapiens (Human). protein_family: Not specified in UniProt protein_domains: bHLH_dom. (IPR011598); Circadian_TF. (IPR050933); HLH_DNA-bd_sf. (IPR036638); Nuc_translocat. (IPR001067); PAC. (IPR001610) provider_config: timeout: null max_retries: 3 parameters: allowed_domains: [] temperature: 0.1 max_embedded_images: 8 citation_count: 16 artifact_count: 1 artifact_sources: edison_answer_artifacts: 1 artifacts: - filename: artifact-00.md path: ARNT-deep-research-falcon_artifacts/artifact-00.md media_type: text/markdown source: edison_answer_artifacts data_storage_id: null description: Edison artifact artifact-00 --- ## Question # Gene Research for Functional Annotation ## ⚠️ CRITICAL: Gene/Protein Identification Context **BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms. ### Target Gene/Protein Identity (from UniProt): - **UniProt Accession:** P27540 - **Protein Description:** RecName: Full=Aryl hydrocarbon receptor nuclear translocator {ECO:0000305}; Short=ARNT protein; AltName: Full=Class E basic helix-loop-helix protein 2; Short=bHLHe2; AltName: Full=Dioxin receptor, nuclear translocator; AltName: Full=Hypoxia-inducible factor 1-beta; Short=HIF-1-beta; Short=HIF1-beta; - **Gene Information:** Name=ARNT {ECO:0000312|HGNC:HGNC:700}; Synonyms=BHLHE2; - **Organism (full):** Homo sapiens (Human). - **Protein Family:** Not specified in UniProt - **Key Domains:** bHLH_dom. (IPR011598); Circadian_TF. (IPR050933); HLH_DNA-bd_sf. (IPR036638); Nuc_translocat. (IPR001067); PAC. (IPR001610) ### MANDATORY VERIFICATION STEPS: 1. **Check if the gene symbol "ARNT" matches the protein description above** 2. **Verify the organism is correct:** Homo sapiens (Human). 3. **Check if protein family/domains align with what you find in literature** 4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP** ### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature: **DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead: - State clearly: "The gene symbol 'ARNT' is ambiguous or literature is limited for this specific protein" - Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism") - Describe the protein based ONLY on the UniProt information provided above - Suggest that the protein function can be inferred from domain/family information ### Research Target: Please provide a comprehensive research report on the gene **ARNT** (gene ID: ARNT, UniProt: P27540) in human. The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims. You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement this with annotations you find in gene/protein databases, but these can be outdated or inaccurate. We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway. We are interested in where in or outside the cell the gene product carries out its function. We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role. Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available. ## Output Question: You are an expert researcher providing comprehensive, well-cited information. Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims. # Gene Research for Functional Annotation ## ⚠️ CRITICAL: Gene/Protein Identification Context **BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms. ### Target Gene/Protein Identity (from UniProt): - **UniProt Accession:** P27540 - **Protein Description:** RecName: Full=Aryl hydrocarbon receptor nuclear translocator {ECO:0000305}; Short=ARNT protein; AltName: Full=Class E basic helix-loop-helix protein 2; Short=bHLHe2; AltName: Full=Dioxin receptor, nuclear translocator; AltName: Full=Hypoxia-inducible factor 1-beta; Short=HIF-1-beta; Short=HIF1-beta; - **Gene Information:** Name=ARNT {ECO:0000312|HGNC:HGNC:700}; Synonyms=BHLHE2; - **Organism (full):** Homo sapiens (Human). - **Protein Family:** Not specified in UniProt - **Key Domains:** bHLH_dom. (IPR011598); Circadian_TF. (IPR050933); HLH_DNA-bd_sf. (IPR036638); Nuc_translocat. (IPR001067); PAC. (IPR001610) ### MANDATORY VERIFICATION STEPS: 1. **Check if the gene symbol "ARNT" matches the protein description above** 2. **Verify the organism is correct:** Homo sapiens (Human). 3. **Check if protein family/domains align with what you find in literature** 4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP** ### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature: **DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead: - State clearly: "The gene symbol 'ARNT' is ambiguous or literature is limited for this specific protein" - Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism") - Describe the protein based ONLY on the UniProt information provided above - Suggest that the protein function can be inferred from domain/family information ### Research Target: Please provide a comprehensive research report on the gene **ARNT** (gene ID: ARNT, UniProt: P27540) in human. The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims. You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement this with annotations you find in gene/protein databases, but these can be outdated or inaccurate. We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway. We are interested in where in or outside the cell the gene product carries out its function. We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role. Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available. # Comprehensive Research Report: Human **ARNT** (UniProt **P27540**) — Functional Annotation ## 0) Target verification (critical identity confirmation) The target protein is **human ARNT** (aryl hydrocarbon receptor nuclear translocator), also widely referred to as **HIF-1β (HIF1B)**. Recent authoritative sources explicitly define ARNT as the constitutive β subunit of hypoxia-inducible factor (HIF) heterodimers and as the nuclear translocator partnering with AHR, consistent with UniProt accession **P27540** and a **class II bHLH–PAS transcription factor** architecture. (ullah2023targetingendothelialhif2αarnt pages 2-4, fornasier2024structuralcharacterizationof pages 13-17) ## 1) Key concepts and definitions (current understanding) ### 1.1 What ARNT is (conceptual definition) **ARNT is not an enzyme or transporter**; it is a **dimerization-competent transcription factor subunit** that enables other signal-responsive transcription factors to bind DNA and activate transcription. In current framing, ARNT is a **class II bHLH–PAS** factor that serves as an **obligate heterodimer partner** for multiple **class I bHLH–PAS** proteins (notably **AHR** and **HIF-α** family members). (fornasier2024structuralcharacterizationof pages 13-17) ### 1.2 Domain architecture and what the domains do bHLH–PAS transcription factors share an N→C architecture comprising: - **bHLH domain**: mediates **DNA binding** and contributes to dimerization. - **PAS-A and PAS-B domains**: contribute to **protein–protein interactions** and complex assembly; in AHR signaling, the stability/specificity of the AHR–ARNT heterodimer is described as being regulated by bHLH and PAS domains. (bahman2024arylhydrocarbonreceptor pages 1-2) - **C-terminal transactivation domain (TAD)**: often functionally important but frequently **intrinsically disordered** and therefore missing from many solved structures. (fornasier2024structuralcharacterizationof pages 13-17) ### 1.3 Core pathway roles and response elements ARNT has two canonical pathway contexts: **(A) AHR (aryl hydrocarbon receptor) pathway (xenobiotic/ligand sensing):** - AHR is described as cytosolic prior to ligand binding; after activation it translocates to the nucleus and **forms a complex with ARNT**, which then binds **xenobiotic response elements (XREs)** to drive transcription of detoxification and immune-response programs. (bahman2024arylhydrocarbonreceptor pages 1-2) - The canonical XRE consensus sequence is explicitly given as **TTGCGTG** (in the context of the DNA-binding interface described for the AhR–ARNT complex). (bahman2024arylhydrocarbonreceptor pages 1-2) - Canonical transcriptional outputs include cytochrome P450 genes such as **CYP1A1, CYP1A2, CYP1B1**. (bahman2024arylhydrocarbonreceptor pages 1-2) **(B) HIF (hypoxia-inducible factor) pathway (oxygen sensing):** - HIF transcription factors are heterodimers of a regulated **HIF-α** subunit and the constitutive β subunit **ARNT (HIF-1β)**. - Under hypoxia, HIF-α translocates to the nucleus and dimerizes with ARNT; the resulting HIF complex binds **hypoxia response elements (HREs)** to activate hypoxia-inducible gene programs, including angiogenesis-related genes (e.g., **VEGF**) and erythropoiesis-related targets (e.g., **EPO**). (ullah2023targetingendothelialhif2αarnt pages 2-4, ullah2023targetingendothelialhif2αarnt pages 1-2) ## 2) Recent developments and latest research (prioritizing 2023–2024) ### 2.1 2024: ARNT as a mechanistic driver of chemoresistance in glioblastoma (primary research) A 2024 **Cell Death & Disease** study reported that **ARNT is upregulated in glioblastoma (GBM)** and that higher ARNT expression correlates with the **mesenchymal subtype** and **poorer survival**. Functionally, ARNT knockdown reduced proliferative, invasive, and stem-like phenotypes, whereas ARNT overexpression enhanced malignant phenotypes. (Publication metadata: 2024-05; URL: https://doi.org/10.1038/s41419-024-06735-1) (alafate2024targetingarntattenuates pages 1-2) Mechanistically, this work proposed a non-canonical ARNT function beyond its classic AHR/HIF heterodimers: ARNT **binds p38α (MAPK14)** to stabilize/activate **p38/MAPK signaling**, contributing to temozolomide chemoresistance. The study mapped this interaction to the **ARNT PAS-A domain** and showed that disrupting the ARNT/p38α interaction (via PAS-A domain manipulation) could restore temozolomide sensitivity. (alafate2024targetingarntattenuates pages 7-10, alafate2024targetingarntattenuates pages 10-11) ### 2.2 2024: AHR–ARNT signaling partners and immunoregulatory framing (authoritative review) A 2024 **Frontiers in Immunology** review (published **15 Aug 2024**) describes AHR as a cytosolic environmental sensor that upon agonist activation translocates to the nucleus and partners with **ARNT (or HIF-1β)**, and the complex binds **XREs** to regulate gene expression relevant to immunity and inflammation. (URL: https://doi.org/10.3389/fimmu.2024.1421346) (bahman2024arylhydrocarbonreceptor pages 1-2) This review provides explicit mechanistic detail relevant to functional annotation: it states that the AHR pathway includes ligand binding, nuclear translocation, and binding to canonical XREs; it also states that the **PAS-A domain** is mainly responsible for **heterodimerization specificity/stability with ARNT**, and that the **bHLH domain** is involved in identifying the XRE consensus sequence **TTGCGTG**. (bahman2024arylhydrocarbonreceptor pages 1-2) ### 2.3 2023: Endothelial HIF2α/ARNT axis in ischemic heart disease (review with translational emphasis) A 2023 review in **Biology** focuses on endothelial HIF2α/ARNT biology and therapeutic implications for ischemic heart disease, emphasizing that: - ARNT (HIF-1β) is the **obligate partner** required for HIF-α transcriptional activity. - HIF1α/ARNT and HIF2α/ARNT heterodimers bind **HREs** to activate transcription. - ARNT contributes to endothelial and cardiovascular biology, including angiogenesis and anti-inflammatory/redox-linked protection (e.g., suppression of NF-κB activity and regulation of ROS). (Publication metadata: 2023-07; URL: https://doi.org/10.3390/biology12070995) (ullah2023targetingendothelialhif2αarnt pages 1-2, ullah2023targetingendothelialhif2αarnt pages 4-6) The same review summarizes developmental/genetic evidence that genetic inactivation of **Arnt** in mice can cause embryonic lethality via abnormal vascular development and reports that loss of endothelial ARNT can lead to severe bleeding and that **nearly 90% of embryos** did not survive beyond **E10.5** in one cited study, highlighting the strong biological constraint on ARNT function in vasculogenesis/angiogenesis. (ullah2023targetingendothelialhif2αarnt pages 6-7) ## 3) Current applications and real-world implementations ### 3.1 ARNT in druggable pathway implementation via AHR therapeutics (real-world example) Although ARNT itself is not (yet) a common direct drug target in clinical practice, **ARNT-containing complexes are already central to approved pharmacology** via AHR modulation. In a 2025 structural paper (included here for mechanistic context of AHR–ARNT axis), Tapinarof is referenced as an approved AHR agonist, illustrating that the **AHR–ARNT transcriptional complex** is a clinically leveraged signaling system. (diao2025structuralbasisfor pages 1-2) ### 3.2 ARNT as a candidate oncology target (preclinical/biomarker applications) The 2024 GBM study positions ARNT as: - a **candidate biomarker** (upregulated in GBM; associated with poorer survival), and - a **candidate therapeutic node**, because disrupting ARNT-dependent stabilization of p38α signaling can restore temozolomide sensitivity in model systems. (alafate2024targetingarntattenuates pages 1-2, alafate2024targetingarntattenuates pages 10-11) ### 3.3 Cardiovascular and ischemic disease conceptual applications The 2023 endothelial HIF2α/ARNT-focused review argues that endothelial ARNT contributes to angiogenesis, endothelial barrier integrity, and suppression of inflammatory cytokine signaling—mechanisms directly relevant to ischemic heart disease pathophysiology and therapy conceptualization. (ullah2023targetingendothelialhif2αarnt pages 2-4, ullah2023targetingendothelialhif2αarnt pages 4-6) ## 4) Expert opinions and analysis (authoritative interpretations) ### 4.1 ARNT as a “shared limiting partner” and pathway competition node A recurring expert-level interpretation across HIF/AHR biology is that ARNT is a **shared partner** required to assemble transcriptionally competent complexes in distinct pathways. This is explicitly discussed in the context of competition/crosstalk (e.g., AHR vs. other transcription factors such as ER for ARNT binding; and pathway framing where ARNT is a central dimerization hub). (haidar2024regulationofthe pages 29-30) ### 4.2 ARNT’s “primary function” in a functional-annotation sense Given the evidence, the primary function of ARNT is best annotated as: - **sequence-specific transcription regulation as a heterodimeric partner** (a structural/organizational role in transcription factor complexes) rather than ligand sensing (AHR) or oxygen sensing (HIF-α subunits). (fornasier2024structuralcharacterizationof pages 13-17, bahman2024arylhydrocarbonreceptor pages 1-2) The most robust mechanistic mapping is: ARNT contributes bHLH/PAS interfaces needed for stable heterodimerization and DNA binding, enabling pathway-specific programs (xenobiotic response via XREs; hypoxia response via HREs). (ullah2023targetingendothelialhif2αarnt pages 2-4, bahman2024arylhydrocarbonreceptor pages 1-2) ## 5) Relevant statistics and recent data points (from the retrieved sources) ### 5.1 Glioblastoma clinical context statistics (disease framing in ARNT-linked study) In the 2024 GBM paper’s introduction, GBM is described as the most aggressive adult brain tumor, with **median survival ~15 months**, and the standard regimen (surgery + radiotherapy + temozolomide) having improved median survival only **from ~12 to 16 months**. (alafate2024targetingarntattenuates pages 1-2) ### 5.2 Developmental/vascular genetics statistic (ARNT constraint) In the 2023 endothelial HIF2α/ARNT review, the loss of endothelial ARNT is summarized as causing severe vascular defects, including a report that **~90% of mouse embryos** did not survive past **E10.5** under endothelial ARNT loss conditions in one cited study. (ullah2023targetingendothelialhif2αarnt pages 6-7) ### 5.3 Disease association evidence (database-derived, triangulation) Open Targets disease–target associations list ARNT evidence across multiple disease areas (examples returned in this retrieval: **cutaneous melanoma**, **neurodegenerative disease**, and several **gynecologic/breast cancer** indications), reflecting multi-domain biomedical relevance (genetics/functional genomics/omics evidence aggregation). (OpenTargets Search: -ARNT) ## 6) Subcellular localization and where ARNT acts ARNT is described as a **nuclear protein** that functions as a dimerization partner for several transcription factors including HIFs and SIM proteins. In AHR biology, AHR is cytosolic prior to ligand activation and then forms a heterodimer with **ARNT in the nucleus** to bind XREs in promoters. (haidar2024regulationofthe pages 29-30) Notably, the 2023 endothelial HIF2α/ARNT review also states that ARNT contains a **nuclear localization signal** and can mediate nuclear translocation of ligand-bound AHR—supporting a nucleus-centered site of action for ARNT-containing transcriptional complexes. (ullah2023targetingendothelialhif2αarnt pages 4-6) ## 7) Pathway-level summary (AHR–ARNT and HIF–ARNT) ### 7.1 AHR–ARNT canonical program 1. Ligand binds AHR in cytosol → 2. Nuclear translocation → 3. AHR dissociates from cytosolic partners and **dimerizes with ARNT** → 4. Complex binds **XREs** (consensus **TTGCGTG**) → 5. Induces detoxification genes including **CYP1A1/1A2/1B1** and broader immune/metabolic outputs. (fornasier2024structuralcharacterizationof pages 13-17, bahman2024arylhydrocarbonreceptor pages 1-2) ### 7.2 HIF–ARNT canonical program 1. Hypoxia stabilizes HIF-α → 2. Nuclear translocation → 3. **HIF-α dimerizes with ARNT (HIF-1β)** → 4. Complex binds **HREs** → 5. Induces hypoxia-adaptation programs (angiogenesis/endothelial survival, metabolism; targets such as **VEGF** and **EPO** cited in the endothelial review context). (ullah2023targetingendothelialhif2αarnt pages 2-4, ullah2023targetingendothelialhif2αarnt pages 1-2) ## 8) Structured summary artifact The following table consolidates identity, domains, partners, DNA elements, localization, and 2023–2024 translational developments. | Category | Summary | |---|---| | Identity/synonyms | - **ARNT** is the human **aryl hydrocarbon receptor nuclear translocator**, synonymous with **HIF-1β/HIF1B** and classified as a **class II bHLH-PAS transcription factor**. - It is the obligate partner for several class I bHLH-PAS proteins, matching UniProt P27540 identity and nomenclature. (ullah2023targetingendothelialhif2αarnt pages 2-4, fornasier2024structuralcharacterizationof pages 13-17) | | Domains | - Conserved architecture includes an **N-terminal bHLH DNA-binding/dimerization domain**, tandem **PAS-A** and **PAS-B** domains, and a **C-terminal transactivation region/TAD** that is largely disordered in structural studies. - In AHR complexes, **PAS-A** helps specify/stabilize heterodimerization, while **PAS-B** can participate in higher-order interface formation. (diao2025structuralbasisfor pages 1-2, fornasier2024structuralcharacterizationof pages 13-17, bahman2024arylhydrocarbonreceptor pages 1-2) | | Core molecular function | - ARNT functions primarily as a **heterodimeric transcription-factor scaffold/partner**, enabling DNA binding and transcriptional activation by AHR and HIF-α proteins rather than acting as an enzyme or transporter. - In hypoxia, ARNT is required for HIF-dependent activation of hypoxia-responsive genes; in xenobiotic signaling, it forms the active **AHR-ARNT** complex. (ullah2023targetingendothelialhif2αarnt pages 1-2, diao2025structuralbasisfor pages 1-2, bahman2024arylhydrocarbonreceptor pages 1-2) | | Key heterodimer partners | - Best-established partners are **AHR**, **HIF-1α**, and **HIF-2α**; additional literature also notes interactions with **SIM proteins** and crosstalk/competition involving **ER** and **AhRR** in pathway regulation. - ARNT-containing complexes are structurally distinct from BMAL1-containing bHLH-PAS complexes. (ullah2023targetingendothelialhif2αarnt pages 4-6, haidar2024regulationofthe pages 29-30, fornasier2024structuralcharacterizationof pages 13-17) | | DNA response elements | - In **HIF** signaling, HIF-α/ARNT heterodimers bind **hypoxia response elements (HREs)** to induce genes such as **VEGF** and **erythropoietin**. - In **AHR** signaling, AHR-ARNT binds **xenobiotic response elements (XREs/DREs)**; the AhR bHLH domain recognizes the canonical **XRE consensus TTGCGTG**. (ullah2023targetingendothelialhif2αarnt pages 2-4, bahman2024arylhydrocarbonreceptor pages 1-2) | | Subcellular localization/transport | - ARNT is mainly described as a **nuclear protein**. - In the AHR pathway, ligand-bound AHR translocates from the cytoplasm to the nucleus and then heterodimerizes with ARNT; structural work supports a transition from chaperone-bound AHR to a nuclear AHR-ARNT transcriptional complex. - Ullah et al. also notes ARNT contains a **nuclear localization signal** and mediates nuclear translocation of ligand-bound AHR. (ullah2023targetingendothelialhif2αarnt pages 4-6, haidar2024regulationofthe pages 29-30, diao2025structuralbasisfor pages 1-2) | | Representative target genes/programs | - **AHR-ARNT** drives detoxification and immune-response programs, including canonical CYP genes such as **CYP1A1, CYP1A2, CYP1B1**. - **HIF-α/ARNT** drives hypoxia-adaptation programs including **angiogenesis, endothelial survival/barrier integrity, anaerobic metabolism**, and induction of **VEGF** and **EPO**. (ullah2023targetingendothelialhif2αarnt pages 1-2, bahman2024arylhydrocarbonreceptor pages 1-2, bahman2024arylhydrocarbonreceptor pages 6-8) | | Recent 2023-2024 developments | - **2023 review:** endothelial ARNT was highlighted as crucial for angiogenesis, anti-inflammatory signaling, redox control, and cardiovascular protection in ischemic heart disease models. - **2024 review:** AhR-ARNT structural/functional work emphasized domain-specific control of XRE recognition and heterodimer stability. - **2024 GBM study:** ARNT was shown to bind **p38α** via its **PAS-A domain**, stabilizing p38/MAPK signaling and promoting chemoresistance. (ullah2023targetingendothelialhif2αarnt pages 4-6, bahman2024arylhydrocarbonreceptor pages 1-2, alafate2024targetingarntattenuates pages 7-10, alafate2024targetingarntattenuates pages 10-11) | | Translational relevance/applications | - ARNT is relevant to **hypoxia biology**, **environmental toxicology**, **inflammation**, **cardiovascular disease**, and **cancer**. - In GBM, disrupting the **ARNT-p38α** interaction restored **temozolomide sensitivity**, supporting ARNT as a therapeutic target. - In AHR pharmacology, the approved AHR agonist **tapinarof** underscores the therapeutic importance of the AHR-ARNT axis. (alafate2024targetingarntattenuates pages 1-2, alafate2024targetingarntattenuates pages 10-11, diao2025structuralbasisfor pages 1-2, OpenTargets Search: -ARNT) | | Quantitative/statistical notes | - GBM has a reported **median survival of ~15 months**, and standard therapy improved median survival only from **~12 to 16 months**; ARNT was reported as **upregulated in GBM** and associated with **poorer survival** and mesenchymal subtype. - In mouse development, loss of endothelial ARNT caused severe cardiovascular/vascular defects, with **nearly 90%** of embryos reportedly not surviving beyond **E10.5** in one cited study. - Open Targets shows ARNT disease associations across **melanoma, neurodegenerative disease, breast ductal adenocarcinoma, and endometrioid adenocarcinomas**. (alafate2024targetingarntattenuates pages 1-2, alafate2024targetingarntattenuates pages 10-11, ullah2023targetingendothelialhif2αarnt pages 6-7, OpenTargets Search: -ARNT) | *Table: This table summarizes verified functional annotation for human ARNT (UniProt P27540), including domains, molecular role, pathway context, localization, and translational relevance. It condenses the most useful evidence for rapid reference while preserving source citations.* ## 9) Limitations of this report (evidence-bound) - For several clinically framed claims in GBM (e.g., exact hazard ratios, precise fold-changes of ARNT expression), the retrieved excerpts confirm directionality (upregulated; poorer survival) but do not provide full numerical effect sizes; therefore this report does not infer missing quantitative values. (alafate2024targetingarntattenuates pages 1-2, alafate2024targetingarntattenuates pages 7-10) - The most detailed 3D structural data on the complete AHR–ARNT DNA-bound complex in the retrieved corpus are 2025; nonetheless, 2024 sources provide domain-level functional interpretation and experimentally grounded DNA consensus and target gene examples for the ARNT-containing complex. (diao2025structuralbasisfor pages 1-2, bahman2024arylhydrocarbonreceptor pages 1-2) ## Key recent sources (URLs, dates) - **Alafate et al. 2024**. *Targeting ARNT attenuates chemoresistance through destabilizing p38α-MAPK signaling in glioblastoma*. **Cell Death & Disease**. Published 2024 (received Jan 6; accepted May 8). https://doi.org/10.1038/s41419-024-06735-1 (alafate2024targetingarntattenuates pages 1-2) - **Bahman et al. 2024-08-15**. *Aryl hydrocarbon receptor: current perspectives on key signaling partners and immunoregulatory role in inflammatory diseases*. **Frontiers in Immunology**. https://doi.org/10.3389/fimmu.2024.1421346 (bahman2024arylhydrocarbonreceptor pages 1-2) - **Ullah et al. 2023-07**. *Targeting Endothelial HIF2α/ARNT Expression for Ischemic Heart Disease Therapy*. **Biology**. https://doi.org/10.3390/biology12070995 (ullah2023targetingendothelialhif2αarnt pages 1-2) References 1. (ullah2023targetingendothelialhif2αarnt pages 2-4): Karim Ullah, Lizhuo Ai, Zainab Humayun, and Rongxue Wu. Targeting endothelial hif2α/arnt expression for ischemic heart disease therapy. Biology, 12:995, Jul 2023. URL: https://doi.org/10.3390/biology12070995, doi:10.3390/biology12070995. This article has 18 citations. 2. (fornasier2024structuralcharacterizationof pages 13-17): E Fornasier. Structural characterization of different proteins as potential drug targets. Unknown journal, 2024. 3. (bahman2024arylhydrocarbonreceptor pages 1-2): Fatemah Bahman, Khubaib Choudhry, Fatema Al-Rashed, Fahd Al-Mulla, Sardar Sindhu, and Rasheed Ahmad. Aryl hydrocarbon receptor: current perspectives on key signaling partners and immunoregulatory role in inflammatory diseases. Frontiers in Immunology, Aug 2024. URL: https://doi.org/10.3389/fimmu.2024.1421346, doi:10.3389/fimmu.2024.1421346. This article has 82 citations and is from a peer-reviewed journal. 4. (ullah2023targetingendothelialhif2αarnt pages 1-2): Karim Ullah, Lizhuo Ai, Zainab Humayun, and Rongxue Wu. Targeting endothelial hif2α/arnt expression for ischemic heart disease therapy. Biology, 12:995, Jul 2023. URL: https://doi.org/10.3390/biology12070995, doi:10.3390/biology12070995. This article has 18 citations. 5. (alafate2024targetingarntattenuates pages 1-2): Wahafu Alafate, Gen Lv, Jiantao Zheng, Haiping Cai, Wei Wu, Yong Yang, Shichao Du, Dong Zhou, and Peng Wang. Targeting arnt attenuates chemoresistance through destabilizing p38α-mapk signaling in glioblastoma. Cell Death & Disease, May 2024. URL: https://doi.org/10.1038/s41419-024-06735-1, doi:10.1038/s41419-024-06735-1. This article has 10 citations and is from a peer-reviewed journal. 6. (alafate2024targetingarntattenuates pages 7-10): Wahafu Alafate, Gen Lv, Jiantao Zheng, Haiping Cai, Wei Wu, Yong Yang, Shichao Du, Dong Zhou, and Peng Wang. Targeting arnt attenuates chemoresistance through destabilizing p38α-mapk signaling in glioblastoma. Cell Death & Disease, May 2024. URL: https://doi.org/10.1038/s41419-024-06735-1, doi:10.1038/s41419-024-06735-1. This article has 10 citations and is from a peer-reviewed journal. 7. (alafate2024targetingarntattenuates pages 10-11): Wahafu Alafate, Gen Lv, Jiantao Zheng, Haiping Cai, Wei Wu, Yong Yang, Shichao Du, Dong Zhou, and Peng Wang. Targeting arnt attenuates chemoresistance through destabilizing p38α-mapk signaling in glioblastoma. Cell Death & Disease, May 2024. URL: https://doi.org/10.1038/s41419-024-06735-1, doi:10.1038/s41419-024-06735-1. This article has 10 citations and is from a peer-reviewed journal. 8. (ullah2023targetingendothelialhif2αarnt pages 4-6): Karim Ullah, Lizhuo Ai, Zainab Humayun, and Rongxue Wu. Targeting endothelial hif2α/arnt expression for ischemic heart disease therapy. Biology, 12:995, Jul 2023. URL: https://doi.org/10.3390/biology12070995, doi:10.3390/biology12070995. This article has 18 citations. 9. (ullah2023targetingendothelialhif2αarnt pages 6-7): Karim Ullah, Lizhuo Ai, Zainab Humayun, and Rongxue Wu. Targeting endothelial hif2α/arnt expression for ischemic heart disease therapy. Biology, 12:995, Jul 2023. URL: https://doi.org/10.3390/biology12070995, doi:10.3390/biology12070995. This article has 18 citations. 10. (diao2025structuralbasisfor pages 1-2): Xiaotong Diao, Qinghong Shang, Mengqi Guo, Yubin Huang, Meina Zhang, Xiaoyu Chen, Yinping Liang, Xiangnan Sun, Fan Zhou, Jingjing Zhuang, Shuang-Jiang Liu, Christoph F. A. Vogel, Fraydoon Rastinejad, and Dalei Wu. Structural basis for the ligand-dependent activation of heterodimeric ahr-arnt complex. Nature Communications, Feb 2025. URL: https://doi.org/10.1038/s41467-025-56574-7, doi:10.1038/s41467-025-56574-7. This article has 43 citations and is from a highest quality peer-reviewed journal. 11. (haidar2024regulationofthe pages 29-30): Rashad Haidar. Regulation of the aryl hydrocarbon receptor (ahr) activity through intracellular transport processes. Dissertation, Jan 2024. URL: https://doi.org/10.17169/refubium-45654, doi:10.17169/refubium-45654. This article has 1 citations. 12. (OpenTargets Search: -ARNT): Open Targets Query (-ARNT, 16 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research. 13. (bahman2024arylhydrocarbonreceptor pages 6-8): Fatemah Bahman, Khubaib Choudhry, Fatema Al-Rashed, Fahd Al-Mulla, Sardar Sindhu, and Rasheed Ahmad. Aryl hydrocarbon receptor: current perspectives on key signaling partners and immunoregulatory role in inflammatory diseases. Frontiers in Immunology, Aug 2024. URL: https://doi.org/10.3389/fimmu.2024.1421346, doi:10.3389/fimmu.2024.1421346. This article has 82 citations and is from a peer-reviewed journal. ## Artifacts - [Edison artifact artifact-00](ARNT-deep-research-falcon_artifacts/artifact-00.md) ## Citations 1. fornasier2024structuralcharacterizationof pages 13-17 2. bahman2024arylhydrocarbonreceptor pages 1-2 3. alafate2024targetingarntattenuates pages 1-2 4. diao2025structuralbasisfor pages 1-2 5. haidar2024regulationofthe pages 29-30 6. alafate2024targetingarntattenuates pages 7-10 7. alafate2024targetingarntattenuates pages 10-11 8. bahman2024arylhydrocarbonreceptor pages 6-8 9. https://doi.org/10.1038/s41419-024-06735-1 10. https://doi.org/10.3389/fimmu.2024.1421346 11. https://doi.org/10.3390/biology12070995 12. https://doi.org/10.3390/biology12070995, 13. https://doi.org/10.3389/fimmu.2024.1421346, 14. https://doi.org/10.1038/s41419-024-06735-1, 15. https://doi.org/10.1038/s41467-025-56574-7, 16. https://doi.org/10.17169/refubium-45654,